|
n
|
43
|
140
|
10
|
28
|
-
|
|
Age
| | | | | |
|
Mean, yrs
|
53.5
|
61.9
|
61.1
|
77.4
|
<0.001*
|
|
Range, yrs
|
16.3 – 78.0
|
35.5 – 93.6
|
45.2 – 74.5
|
53.1 – 95.0
| |
|
Gender, no. (%)
| | | | |
0.01*
|
|
Male
|
21 (48.8)
|
95 (67.9)
|
6 (60.0)
|
11 (39.3)
| |
|
Female
|
22 (51.2)
|
45 (32.1)
|
4 (40.0)
|
17 (60.7)
| |
|
Charlston Comorbidity Index, mean score (range)
|
1.9 (0–9)
|
2.3 (0–7)
|
3.0 (0–7)
|
5.4 (0–9)
|
<0.001*
|
|
Site of tumor, no. (%)
| | | | | |
|
Tongue,
|
23 (53.5)
|
51 (36.4)
|
6 (60)
|
8 (28.6)
|
0.92
|
|
Floor of Mouth
|
8 (18.6)
|
37 (26.4)
|
2 (20.0)
|
7 (25.0)
| |
|
Other
|
12 (27.9)
|
52 (37.1)
|
2 (20)
|
13 (46.4)
| |
|
cT-stage, no. (%)
| | | | |
0.16
|
|
1
|
1 (2.3)
|
9 (6.4)
|
1 (10.0)
|
0 (0.0)
| |
|
2
|
15 (34.9)
|
39 (27.9)
|
2 (20.0
|
5 (17.8)
| |
|
3
|
13 (30.2)
|
28 (20.0)
|
1 (10.0)
|
4 (14.2)
| |
|
4
|
14 (32.6)
|
64 (45.7)
|
6 (60.0)
|
19 (67.8)
| |
|
cN-stage, no. (%)
| | | | |
<0.001*
|
|
N0
|
2 (4.7)
|
39 (27.9)
|
2 (20.0)
|
12 (42.9)
| |
|
N1
|
4 (9.3)
|
52 (37.1)
|
3 (30.0)
|
11 (39.3)
| |
|
N2a
|
3 (7.0)
|
23 (16.4)
|
2 (20.0)
|
2 (7.1)
| |
|
N2b
|
18 (41.9)
|
15 (10.7)
|
2 (20.0)
|
2 (7.1)
| |
|
N2c
|
14 (32.6)
|
7 (5.0)
|
0 (0.0)
|
1 (3.6)
| |
|
N3
|
2 (4.7)
|
4 (2.9)
|
1 (10.0)
|
0 (0.0)
| |
|
Perineural Invasion, no. (%)
|
21 (48.8)
|
34 (24.3)
|
/
|
/
|
0.004*
|
|
Lymph-vascular Invasion, no. (%)
|
31 (72.1)
|
24 (17.1)
|
/
|
/
|
<0.001*
|
|
Extracapsular spread, no. (%)
|
27 (62.8)
|
46 (32.9)
|
/
|
/
|
0.001*
|
|
Overall stage, no. (%)
| | | | |
0.60
|
|
III
|
4 (9.3)
|
46 (32.9)
|
0 (0)
|
7 (25)
| |
|
IV
|
39 (90.7)
|
94 (67.2)
|
10 (100)
|
21 (75)
| |
|
Death, no. (%)
|
17 (39.5)
|
89 (63.6)
|
10 (100)
|
26 (92.9)
| |
|
Death, cause (%)
| | | | |
0.37
|
|
Primary Cancer
|
47.1
|
85.4
|
90
|
92.3
|
|
Other Cancer
|
23.5
|
5.6
|
0
|
3.8
|
|
Non-Cancer
|
29.4
|
10.1
|
10
|
11.5
|
